TrialBMC cancer2012

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

Dimitrios Pectasides et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.